hoodb.com

基石藥業:腫瘤藥物CS5001全球多中心Ib期臨床試驗完成首例患者入組

|

You are leaving and open the following URL" of about "i b" news

news.google.com/rss/articles/CBMihgFBVV95cUxORjFTYUUxZWhOR1RtaVdFSTA1QXlreFNqMnZoalFqZ0RMMnFLd0RQTEFxcU80VDR4SXRrSDFWaUN0UmVXSHVNbDJ5bDJmai03ak0yb0FwMWEwR0g1NG1GQklJcVhsRzgyckh1d2RtU2ZrczN2V2M3VldWcXZYRDJWWWdjQ0kxZw?oc=5


Continue Opne >

i b: 基石藥業:腫瘤藥物CS5001全球多中心Ib期臨床試驗完成首例患者入組


More i b news:



Warning: filemtime(): stat failed for aCache/aaa/gnews/SA/i b.xml in /var/www/hoodb/function.php on line 339
1735185653-
Warning: file_put_contents(aCache/aaa/gnews/SA//i b.xml): Failed to open stream: No space left on device in /var/www/hoodb/function.php on line 348

About i b

from
1735185654-1735066515

Warning: filemtime(): stat failed for aCache/search/sa/i b in /var/www/hoodb/function.php on line 339
1735185654-

i b, 基石藥業:腫瘤藥物CS5001全球多中心Ib期臨床試驗完成首例患者入組 2022 i b

基石藥業:腫瘤藥物CS5001全球多中心Ib期臨床試驗完成首例患者入組

Choose Your Country or Region


Back to Top



基石藥業:腫瘤藥物CS5001全球多中心Ib期臨床試驗完成首例患者入組

Copyright © 2020-2021 hoodb.com. All Rights Reserved.